Gastrointestinal Bleeding Treatment

Global Gastrointestinal Bleeding Treatment Market to Reach US$1.2 Billion by 2030

The global market for Gastrointestinal Bleeding Treatment estimated at US$845.9 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Endoscopic Hemostatic Devices, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$704.8 Million by the end of the analysis period. Growth in the Closure Devices segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$230.5 Million While China is Forecast to Grow at 9.0% CAGR

The Gastrointestinal Bleeding Treatment market in the U.S. is estimated at US$230.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$238.8 Million by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Gastrointestinal Bleeding Treatment Market – Key Trends & Drivers Summarized

Why Is Gastrointestinal Bleeding Treatment Becoming More Advanced and Effective?

Gastrointestinal (GI) bleeding treatment has evolved significantly in recent years, driven by advancements in diagnostic techniques, minimally invasive procedures, and targeted pharmacological therapies. GI bleeding, which can occur in the upper or lower digestive tract, is a serious medical condition that requires prompt diagnosis and intervention to prevent life-threatening complications. The most common causes include peptic ulcers, diverticulosis, inflammatory bowel disease (IBD), esophageal varices, and colorectal cancer.

The increasing prevalence of GI disorders, coupled with the aging global population, has heightened the demand for effective treatment solutions. Endoscopic hemostasis techniques, such as clip placement, argon plasma coagulation (APC), and injection therapy, have become the gold standard for controlling active bleeding in most cases. Additionally, the integration of artificial intelligence (AI) in endoscopic imaging has enhanced the early detection of bleeding sources, improving patient outcomes. As healthcare providers continue to adopt advanced treatment modalities, the landscape of GI bleeding management is shifting toward faster, safer, and more efficient interventions.

Which Treatment Modalities Are Driving Innovation in Gastrointestinal Bleeding Management?

The management of gastrointestinal bleeding has been revolutionized by a combination of endoscopic, pharmacological, and surgical interventions. Endoscopic procedures remain the primary treatment approach for acute GI bleeding, with techniques such as thermal coagulation, band ligation, and hemostatic spray technology providing immediate hemostasis. Capsule endoscopy and deep enteroscopy have also enhanced the ability to diagnose and treat obscure GI bleeding in the small intestine, an area previously difficult to access with conventional endoscopy.

Pharmacological treatments, including proton pump inhibitors (PPIs), vasoactive drugs, and tranexamic acid, play a crucial role in preventing rebleeding and managing underlying conditions. In severe cases, interventional radiology procedures such as transarterial embolization (TAE) are utilized to control bleeding when endoscopic methods fail. For patients with refractory GI bleeding, surgical intervention, including partial colectomy or gastrectomy, may be required. The growing adoption of combination therapy, integrating endoscopic and pharmacological treatments, has improved overall patient survival rates and reduced hospitalization costs.

How Are Technological Advancements Enhancing Gastrointestinal Bleeding Treatment?

Recent technological advancements have significantly improved the diagnosis, treatment, and prevention of gastrointestinal bleeding. AI-assisted endoscopy is one of the most transformative innovations, enabling real-time image analysis and automated detection of bleeding lesions. This technology enhances physician accuracy, reduces procedure times, and improves early detection of high-risk lesions. Additionally, the development of advanced hemostatic agents, including sprayable biologics and bioabsorbable hemostats, has expanded treatment options for complex bleeding cases.

Another breakthrough is the use of robotic-assisted endoscopic procedures, which offer greater precision and maneuverability in treating difficult-to-reach areas of the gastrointestinal tract. Smart capsule endoscopy has also gained traction, allowing for non-invasive visualization of the small intestine without the need for sedation or radiation exposure. Furthermore, advances in gene therapy and regenerative medicine are being explored to treat chronic GI conditions that predispose patients to recurrent bleeding episodes. These technological innovations are reshaping the future of GI bleeding management, enhancing both patient outcomes and healthcare efficiency.

What Factors Are Fueling the Growth of the Gastrointestinal Bleeding Treatment Market?

The growth in the gastrointestinal bleeding treatment market is driven by several factors, including the rising prevalence of GI disorders, increasing adoption of advanced endoscopic techniques, and the expansion of minimally invasive treatment options. The aging population, particularly in developed nations, has led to a higher incidence of peptic ulcers, diverticulosis, and esophageal varices, all of which contribute to GI bleeding cases.

Technological innovations, such as AI-assisted endoscopy, robotic procedures, and hemostatic biomaterials, have enhanced the effectiveness of GI bleeding treatment, prompting greater adoption by healthcare providers. The expansion of outpatient and ambulatory surgical centers has also increased patient access to minimally invasive procedures, reducing the need for hospitalization. Additionally, government initiatives promoting early screening and diagnostic programs for colorectal cancer and GI disorders have further fueled market growth. As the demand for effective and less invasive GI bleeding treatments continues to rise, the market is expected to expand, driven by continuous advancements in medical technology and patient-centered care solutions.

SCOPE OF STUDY:

The report analyzes the Gastrointestinal Bleeding Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Endoscopic Hemostatic Devices, Closure Devices, Other Products); GI Tract Division (Upper GI Tract, Lower GI Tract); Onset (Acute Onset, Chronic Onset); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Abbott Laboratories
• AngioDynamics
• Boston Scientific Corporation
• BTG International Ltd.
• CONMED Corporation
• Cook Group
• ERBE Elektromedizin GmbH
• Fujifilm Holdings Corporation
• Johnson & Johnson
• Medline Industries, Inc.
• Medtronic plc
• Merit Medical Systems
• Olympus Corporation
• Ovesco Endoscopy AG
• Pentax Medical (HOYA Corporation)
• Salix Pharmaceuticals
• STERIS plc
• Teleflex Incorporated
• US Medical Innovations, LLC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.